Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
| Status: | Completed |
|---|---|
| Conditions: | Other Indications |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 30 - 75 |
| Updated: | 7/13/2018 |
| Start Date: | October 2009 |
The long-term objective of this research is to develop a non-invasive approach for early
assessment of which patients are at high risk for future development of skeletal muscle
atrophy. The investigators hypothesize that the rate constant for the terminal portion of the
isotope decay curve following ingestion of a single oral dose of deuterated-3-methylhistidine
(D-3MH) provides an accurate measure of this increased risk and that this rate constant can
be measured non-invasively from timed spot urine samples.
assessment of which patients are at high risk for future development of skeletal muscle
atrophy. The investigators hypothesize that the rate constant for the terminal portion of the
isotope decay curve following ingestion of a single oral dose of deuterated-3-methylhistidine
(D-3MH) provides an accurate measure of this increased risk and that this rate constant can
be measured non-invasively from timed spot urine samples.
Inclusion Criteria:
- Male
- 30-75 years old
- Body Mass Index (BMI) <27 kg/m2
Exclusion Criteria:
- Uncontrolled hypertension
- Glomerular filtration rate less than 60 mL/min/1.73 m2
- History of recurrent gastrointestinal bleeding
- Unable or unwilling to provide informed consent
- Ongoing anti-coagulant therapy
We found this trial at
1
site
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
